Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Oncology Group
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer.
II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation.
EXPLORATORY OBJECTIVES:
I. Evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma.
OUTLINE:
Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
Age
18–50
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Received upfront therapies for osteosarcoma, which included cisplatin, (with or without other agents)
Patient must have completed cancer treatment \>= 2 years prior to study enrollment
Osteosarcoma survivors without a systemically treated relapse or subsequent malignancy
* Note: History of relapse or second malignancy is permitted if treated with local therapy only (e.g. surgery, radiation)
Able to speak, read and write in English, French or Spanish
All patients and/or their parents or legal guardians must sign a written informed consent
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Clareo Health | Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
